{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:59:16Z","timestamp":1789210756153,"version":"build-2803163510"},"reference-count":48,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,9]]},"DOI":"10.18632\/oncotarget.10541","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T14:29:50Z","timestamp":1468333790000},"page":"51651-51664","source":"Crossref","is-referenced-by-count":15,"title":["Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Kamilla M.E.","family":"Laidlaw","sequence":"first","affiliation":[{"name":"Paul O'Gorman Leukemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, G12 0ZD, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Berhan","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, G12 0ZD, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannino","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, G12 0ZD, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Frank","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Bonner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Atlanta Veterans Administration Hospital, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Perrotti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather G.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Gartnavel General Hospital, Glasgow, G12 0ZD, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack L.","family":"Arbiser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Atlanta Veterans Administration Hospital, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.stem.2010.06.014","article-title":"Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis","volume":"7","author":"Passegue","year":"2010","journal-title":"Cell Stem Cell"},{"key":"2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3109\/10428194.2012.696313","article-title":"Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation","volume":"53","author":"Skorski","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.exphem.2013.09.007","article-title":"Resilient and resourceful: genome maintenance strategies in hematopoietic stem cells","volume":"41","author":"Passegue","year":"2013","journal-title":"Exp Hematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.freeradbiomed.2011.06.033","article-title":"Cross talk between mitochondria and NADPH oxidases","volume":"51","author":"Dikalov","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/stem.1678","article-title":"Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting","volume":"32","author":"Holyoake","year":"2014","journal-title":"Stem Cells"},{"key":"6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Shah","year":"2014","journal-title":"Leuk Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Zhang","year":"2013","journal-title":"J Clin Invest"},{"key":"8","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Neviani","year":"2013","journal-title":"Lancet Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Marcucci","year":"2007","journal-title":"J Clin Invest"},{"key":"10","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Li","year":"2014","journal-title":"Sci Transl Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Stoklosa","year":"2013","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Holyoake","year":"2012","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"7114","DOI":"10.1074\/jbc.M804801200","article-title":"Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells","volume":"284","author":"Chandra","year":"2009","journal-title":"J Biol Chem"},{"key":"14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: insights and therapeutic opportunities","volume":"16","author":"Passegue","year":"2015","journal-title":"Cell Stem Cell"},{"key":"15","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4161\/cc.25334","article-title":"Identifying new small molecule anti-invasive compounds for glioma treatment","volume":"12","author":"Bellamkonda","year":"2013","journal-title":"Cell Cycle"},{"key":"16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03401997","article-title":"Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase","volume":"8","author":"Arbiser","year":"2002","journal-title":"Mol Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2013.15","article-title":"Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations","volume":"27","author":"Kogan","year":"2013","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.0804336105","article-title":"A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells","volume":"105","author":"Tonks","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Bruner-Klisovic","year":"2005","journal-title":"Cancer Cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","article-title":"Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate","volume":"116","author":"Lehn","year":"2010","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Holyoake","year":"2007","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Bhatia","year":"2011","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"White","year":"2013","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"Lancet Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm1388","article-title":"Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells","volume":"12","author":"Suda","year":"2006","journal-title":"Nat Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Holyoake","year":"2012","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-08-0405","article-title":"Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growthand","volume":"14","author":"Arbiser","year":"2008","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1078-0432.CCR-14-0166","article-title":"SETting OP449 into the PP2A-activating drug family","volume":"20","author":"Perrotti","year":"2014","journal-title":"Clin Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0145-2126(02)00347-8","article-title":"Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells","volume":"27","author":"Omay","year":"2003","journal-title":"Leuk Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Goris","year":"2001","journal-title":"Biochem J"},{"key":"31","first-page":"127ra136","article-title":"Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma","volume":"4","author":"Bellamkonda","year":"2012","journal-title":"Sci Transl Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40880-016-0084-4","article-title":"Future options of anti-angiogenic cancer therapy","volume":"35","author":"Cao","year":"2016","journal-title":"Chin J Cancer"},{"key":"33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrendo.2014.114","article-title":"VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs","volume":"10","author":"Cao","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"34","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/ncomms3129","article-title":"Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis","volume":"4","author":"Larsson","year":"2013","journal-title":"Nat Commun"},{"key":"35","doi-asserted-by":"crossref","first-page":"e1400244","DOI":"10.1126\/sciadv.1400244","article-title":"PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors","volume":"1","author":"Cao","year":"2015","journal-title":"Sci Adv"},{"key":"36","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1038\/ncomms5944","article-title":"TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling","volume":"5","author":"Yang","year":"2014","journal-title":"Nat Commun"},{"key":"37","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1182\/blood-2005-01-0226","article-title":"Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels","volume":"106","author":"Cao","year":"2005","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1158\/0008-5472.CAN-14-2819","article-title":"Novel mechanism of macrophage-mediated metastasis revealed in a zebrafish model of tumor development","volume":"75","author":"Cao","year":"2015","journal-title":"Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"E2900","DOI":"10.1073\/pnas.1503500112","article-title":"VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients","volume":"112","author":"Cao","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"40","article-title":"Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy","author":"Cao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"41","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2004-10-4135","article-title":"The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells","volume":"105","author":"Jordan","year":"2005","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","article-title":"The NF-kappaB subunit Rel A is associated withsurvival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target","volume":"111","author":"Rowntree","year":"2008","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia","volume":"285","author":"Chen","year":"2010","journal-title":"J Biol Chem"},{"key":"44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","article-title":"Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis","volume":"1","author":"Miyoshi","year":"1983","journal-title":"Int J Cell Cloning"},{"key":"45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"46","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Kantarjian","year":"1993","journal-title":"Cancer Res"},{"key":"47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V54.3.713.713","article-title":"Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia","volume":"54","author":"Gallo","year":"1979","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571","volume":"99","author":"Holyoake","year":"2002","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:27:20Z","timestamp":1589279240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":48,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2016,8,9]]}},"alternative-id":["10541","27438151"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10541","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]}}}